Larimar Total Current Assets vs Retained Earnings Analysis

LRMR Stock

USD 1.96 0.02 1.01%

Larimar Therapeutics financial indicator trend analysis is infinitely more than just investigating Larimar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Larimar Therapeutics is a good investment. Please check the relationship between Larimar Therapeutics Total Current Assets and its Retained Earnings accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.

Total Current Assets vs Retained Earnings

Total Current Assets vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Larimar Therapeutics Total Current Assets account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.

The correlation between Larimar Therapeutics' Total Current Assets and Retained Earnings is -0.72. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Larimar Therapeutics, assuming nothing else is changed. The correlation between historical values of Larimar Therapeutics' Total Current Assets and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Larimar Therapeutics are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Current Assets i.e., Larimar Therapeutics' Total Current Assets and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.72

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Larimar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Larimar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Larimar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Larimar Stock, please use our How to Invest in Larimar Therapeutics guide.At this time, Larimar Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 04/08/2025, Enterprise Value is likely to grow to about 218.6 M, while Selling General Administrative is likely to drop slightly above 12.9 M.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	36.5M	41.8M	90.9M	47.8M
Cost Of Revenue	272K	311K	357.7K	375.5K

Total Operating Expenses Cost Of Revenue

Larimar Therapeutics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Non Currrent Assets Other	Net Receivables	Short Long Term Debt Total	Accounts Payable	Short Term Investments	Non Current Liabilities Total	Short Term Debt	Current Deferred Revenue	Other Assets	Long Term Debt
Common Stock Shares Outstanding		0.43	0.89	0.78	0.42	0.6	-0.08	-0.39	0.11	0.6	0.39	0.89	0.39	0.38	0.41	0.84	0.72	-0.61	-0.31	-0.26	0.54	-0.37	-0.32	-0.48	0.94	0.15
Total Assets	0.43		0.63	0.77	1.0	0.41	-0.41	-0.71	0.51	0.32	1.0	0.55	0.86	0.81	1.0	0.76	-0.07	-0.36	-0.03	0.27	0.63	-0.05	0.34	-0.21	0.42	0.37
Other Current Liab	0.89	0.63		0.96	0.62	0.42	-0.11	-0.58	0.18	0.37	0.61	0.95	0.57	0.55	0.63	0.88	0.59	-0.46	-0.19	0.0	0.78	-0.24	-0.04	-0.32	0.79	0.27
Total Current Liabilities	0.78	0.77	0.96		0.75	0.41	-0.18	-0.67	0.29	0.33	0.75	0.88	0.71	0.69	0.76	0.91	0.35	-0.48	-0.09	0.14	0.79	-0.14	0.1	-0.37	0.69	0.34
Total Stockholder Equity	0.42	1.0	0.62	0.75		0.41	-0.41	-0.66	0.49	0.32	0.99	0.53	0.83	0.74	0.99	0.74	-0.05	-0.35	-0.12	0.3	0.65	-0.09	0.29	-0.14	0.42	0.32
Property Plant And Equipment Net	0.6	0.41	0.42	0.41	0.41		-0.54	-0.11	0.49	0.99	0.36	0.5	0.33	0.35	0.38	0.47	0.34	-0.78	-0.36	-0.22	-0.05	-0.39	-0.34	-0.65	0.52	0.1
Net Debt	-0.08	-0.41	-0.11	-0.18	-0.41	-0.54		0.07	-0.95	-0.51	-0.39	-0.21	-0.18	-0.28	-0.39	-0.14	0.01	0.27	0.14	0.09	0.23	0.23	0.01	0.17	0.1	-0.03
Retained Earnings	-0.39	-0.71	-0.58	-0.67	-0.66	-0.11	0.07		-0.32	-0.03	-0.72	-0.48	-0.92	-0.85	-0.72	-0.77	0.09	0.17	-0.47	0.11	-0.53	-0.4	-0.72	0.35	-0.39	-0.75
Cash	0.11	0.51	0.18	0.29	0.49	0.49	-0.95	-0.32		0.44	0.5	0.27	0.38	0.5	0.5	0.29	-0.11	-0.26	0.13	-0.12	-0.15	-0.06	0.24	-0.31	-0.06	0.24
Non Current Assets Total	0.6	0.32	0.37	0.33	0.32	0.99	-0.51	-0.03	0.44		0.27	0.46	0.24	0.26	0.29	0.42	0.41	-0.73	-0.4	-0.28	-0.1	-0.46	-0.41	-0.61	0.54	0.02
Cash And Short Term Investments	0.39	1.0	0.61	0.75	0.99	0.36	-0.39	-0.72	0.5	0.27		0.51	0.86	0.8	1.0	0.75	-0.1	-0.31	-0.01	0.29	0.64	-0.03	0.37	-0.17	0.39	0.37
Other Current Assets	0.89	0.55	0.95	0.88	0.53	0.5	-0.21	-0.48	0.27	0.46	0.51		0.46	0.52	0.53	0.82	0.61	-0.54	-0.17	-0.11	0.62	-0.24	-0.14	-0.41	0.76	0.26
Other Stockholder Equity	0.39	0.86	0.57	0.71	0.83	0.33	-0.18	-0.92	0.38	0.24	0.86	0.46		0.9	0.87	0.77	-0.18	-0.36	0.29	0.07	0.53	0.3	0.61	-0.41	0.4	0.69
Total Liab	0.38	0.81	0.55	0.69	0.74	0.35	-0.28	-0.85	0.5	0.26	0.8	0.52	0.9		0.8	0.73	-0.14	-0.29	0.48	0.04	0.4	0.19	0.57	-0.57	0.35	0.56
Total Current Assets	0.41	1.0	0.63	0.76	0.99	0.38	-0.39	-0.72	0.5	0.29	1.0	0.53	0.87	0.8		0.76	-0.09	-0.33	-0.02	0.29	0.64	-0.03	0.36	-0.19	0.41	0.37
Common Stock	0.84	0.76	0.88	0.91	0.74	0.47	-0.14	-0.77	0.29	0.42	0.75	0.82	0.77	0.73	0.76		0.32	-0.54	-0.02	-0.13	0.69	-0.06	0.14	-0.49	0.84	0.46
Non Currrent Assets Other	0.72	-0.07	0.59	0.35	-0.05	0.34	0.01	0.09	-0.11	0.41	-0.1	0.61	-0.18	-0.14	-0.09	0.32		-0.15	-0.44	-0.34	0.29	-0.64	-0.55	-0.05	0.64	-0.31
Net Receivables	-0.61	-0.36	-0.46	-0.48	-0.35	-0.78	0.27	0.17	-0.26	-0.73	-0.31	-0.54	-0.36	-0.29	-0.33	-0.54	-0.15		0.36	0.14	-0.09	-0.04	0.31	0.67	-0.56	-0.42
Short Long Term Debt Total	-0.31	-0.03	-0.19	-0.09	-0.12	-0.36	0.14	-0.47	0.13	-0.4	-0.01	-0.17	0.29	0.48	-0.02	-0.02	-0.44	0.36		-0.14	-0.16	0.57	0.77	-0.32	-0.3	0.44
Accounts Payable	-0.26	0.27	0.0	0.14	0.3	-0.22	0.09	0.11	-0.12	-0.28	0.29	-0.11	0.07	0.04	0.29	-0.13	-0.34	0.14	-0.14		0.39	-0.08	0.07	0.34	-0.26	-0.22
Short Term Investments	0.54	0.63	0.78	0.79	0.65	-0.05	0.23	-0.53	-0.15	-0.1	0.64	0.62	0.53	0.4	0.64	0.69	0.29	-0.09	-0.16	0.39		-0.12	0.14	0.12	0.58	0.16
Non Current Liabilities Total	-0.37	-0.05	-0.24	-0.14	-0.09	-0.39	0.23	-0.4	-0.06	-0.46	-0.03	-0.24	0.3	0.19	-0.03	-0.06	-0.64	-0.04	0.57	-0.08	-0.12		0.67	-0.11	-0.34	0.8
Short Term Debt	-0.32	0.34	-0.04	0.1	0.29	-0.34	0.01	-0.72	0.24	-0.41	0.37	-0.14	0.61	0.57	0.36	0.14	-0.55	0.31	0.77	0.07	0.14	0.67		-0.02	-0.29	0.66
Current Deferred Revenue	-0.48	-0.21	-0.32	-0.37	-0.14	-0.65	0.17	0.35	-0.31	-0.61	-0.17	-0.41	-0.41	-0.57	-0.19	-0.49	-0.05	0.67	-0.32	0.34	0.12	-0.11	-0.02		-0.45	-0.43
Other Assets	0.94	0.42	0.79	0.69	0.42	0.52	0.1	-0.39	-0.06	0.54	0.39	0.76	0.4	0.35	0.41	0.84	0.64	-0.56	-0.3	-0.26	0.58	-0.34	-0.29	-0.45		0.15
Long Term Debt	0.15	0.37	0.27	0.34	0.32	0.1	-0.03	-0.75	0.24	0.02	0.37	0.26	0.69	0.56	0.37	0.46	-0.31	-0.42	0.44	-0.22	0.16	0.8	0.66	-0.43	0.15

Click cells to compare fundamentals

Larimar Therapeutics Account Relationship Matchups

Larimar Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	11.9M	17.2M	25.8M	43.9M	61.3M	64.3M
Total Assets	104.7M	78.7M	126.4M	95.9M	200.2M	112.2M
Other Current Liab	5.3M	6.0M	7.8M	7.4M	20.9M	21.9M
Total Current Liabilities	9.0M	8.8M	10.7M	9.5M	24.4M	25.6M
Total Stockholder Equity	89.7M	64.4M	110.9M	81.7M	171.8M	95.4M
Property Plant And Equipment Net	5.0M	4.5M	3.7M	3.8M	3.7M	2.0M
Net Debt	(61.6M)	(64.1M)	(21.4M)	(21.2M)	(28.1M)	(29.5M)
Retained Earnings	(65.6M)	(116.3M)	(151.6M)	(188.6M)	(269.2M)	(255.7M)
Cash	68.1M	70.1M	26.8M	26.7M	33.2M	41.3M
Non Current Assets Total	6.7M	6.5M	5.7M	5.8M	4.9M	2.9M
Cash And Short Term Investments	92.6M	70.1M	118.4M	86.8M	183.5M	105.6M
Liabilities And Stockholders Equity	104.7M	78.7M	126.4M	95.9M	200.2M	112.2M
Other Current Assets	5.3M	1.9M	2.3M	3.4M	11.9M	12.4M
Other Stockholder Equity	155.3M	180.6M	262.5M	270.2M	440.9M	249.2M
Total Liab	15.0M	14.3M	15.5M	14.2M	28.4M	16.7M
Total Current Assets	98.0M	72.2M	120.7M	90.2M	195.3M	109.3M
Common Stock	6K	15K	18K	43K	64K	67.2K
Non Currrent Assets Other	419K	669K	638K	659K	1.2M	1.3M
Net Receivables	1.5M	158K	32K	208K	187.2K	177.8K
Short Long Term Debt Total	6.5M	6.0M	5.4M	5.5M	5.1M	6.9M
Accounts Payable	2.6M	1.7M	1.7M	1.3M	2.4M	2.2M
Short Term Investments	24.5M	0.0	91.6M	60.0M	150.2M	157.7M
Non Current Liabilities Total	6.0M	5.4M	4.8M	4.7M	4.1M	6.8M
Accumulated Other Comprehensive Income	1K	0.0	(31K)	81K	93.2K	97.8K
Short Term Debt	1.0M	1.2M	1.2M	837K	1.1M	1.5M
Other Assets	26K	90K	0.0	2.0M	2.3M	2.4M
Capital Surpluse	444.2M	449.9M	155.3M	262.5M	236.2M	272.9M
Property Plant And Equipment Gross	5.0M	4.5M	3.7M	5.0M	5.3M	3.7M
Property Plant Equipment	361K	5.0M	4.5M	831K	955.7K	1.8M
Net Tangible Assets	(694K)	89.7M	64.4M	110.9M	127.5M	133.9M
Capital Lease Obligations	6.5M	6.0M	5.4M	5.5M	5.1M	5.3M
Net Invested Capital	89.7M	64.4M	110.9M	81.7M	171.8M	94.9M
Net Working Capital	89.0M	63.4M	110.0M	80.7M	170.9M	94.0M

Pair Trading with Larimar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Larimar Stock

0.84

Agilent Technologies

Pair Corr

Moving against Larimar Stock

0.56	VALN	Valneva SE ADR	Pair Corr
0.41	DVAX	Dynavax Technologies	Pair Corr

The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.

The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Larimar Stock Analysis

When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC